Pfannenschmidt, Gerd: „Der Effekt von Antithrombin III auf die pulmonalvaskuläre Freisetzung von Big Endothelin-1, Endothelin-1 und Prostanoiden unter septischen und nichtseptischen Bedingungen sowie seine Mechanismen“

Literatur

[1] Voelkel NF. The adult respiratory distress syndrome. Klin Wschr. 1989; 67: 559.

[2] Walmrath D, Grimminger F, Lasch HG, Seeger W. Sepsis und das akute Lungenversagen - eine mögliche Rolle bakterieller Exotoxine. medwelt. 1993; 44: 23-32.

[3] Walmrath D, Griebner M, Kolb B, Grimminger F, Galanos C, Schade U, Seeger W. Endotoxin primes perfused rabbit lungs for enhanced vasoconstrictor response to staphylococcal alpha-toxin. Am Rev Respir Dis. 1993; 148: 1179-86.

[4] Fowler AA, Hamman RF, Zerbe GO, Benson K, Hyers TM. Adult respiratory distress syndrom. Prognosis after onset. Am Rev Respir Dis. 1985; 132: 472-78.

[5] Montgomery AB, Stager MA, Carrico CJ, Hudson LD. Causes of mortality in patients with the adult respiratory distress syndrom. Am Rev Respir Dis. 1985; 132: 485-89.

[6] Petty TL. Indicators of risk, course, and prognosis in adult respiratory distress syndrom (ARDS). Am Rev Respir Dis. 1985; 132: 471-72.

[7] Druml W, Stelzner H, Waldhäusl W, Lenz K, Hammerle A, Vierhapper H, Gasic S, Wagner OF. Endothelin-1 in adult respiratory distress syndrome. Am Rev Respir Dis. 1993; 148: 1169-73.

[8] Dantzker DR, Brook CJ, Dehart P, Lynch JP, Weg JG. Ventilation-perfusion distributions in the adult respiratory distress syndrome. Am Rev Respir Dis. 1979; 120: 1039-52.

[9] Ralph DD, Robertson HAT, Weaver LJ, Hlastala MP, Carrico CJ, Hudson LD. Distribution of ventilation and perfusion during positive end-expiratory pressure in the adult respiratory distress syndrome. Am Rev Respir Dis. 1985; 131: 54-60.

[10] Quirmbach G, Müller S. Medizinische Mikrobiologie 8.Auflage. Chapman&Hall Weinheim. 1995; 3-4.

[11] Zetkin M, Schaldach H. Wörterbuch der Medizin 15.Auflage. Ullstein Mosby Berlin. 1992; 1252.

[12] Brigham KL, Meyrick B. Endotoxin and lung injury. Am Rev Respir Dis. 1977; 133: 913-27.

[13] Brigham KL, Meyrick B. Interactions of granulocytes with the lung. Circ Res. 1984; 54: 623-35.

[14] Kelley J. State of the art: Cytokines of the lung. Am Rev Respir Dis. 1990; 141: 765-88.

[15] Sibille Y, Reynolds HY. Macrophages and polymorphnuclear neutrophils in lung defense and injury. Am Rev Respir Dis. 1990; 141: 471-501.

[16] Curzen NP, Kaddoura S, Griffith MJD, Evans TW. Endothelin-1 in rat endotoxemia: mRNA expression and vasoreactivity in pulmonary and systemic circulations. Am J Physiol. 1997; 41: H2353-60.

[17] Weitzberg E, Hemsen A, Rudehill A, Modin A, Wanacek M, Lundberg JM. Bosentan-improved cardiopulmonary vascular performance and increased plasma levels of endothelin-1 in porcine endotoxin shock. Br J Pharmacol. 1996; 118: 617-26.

[18] Nakamura T, Kasai K, Sekiguchi Y, Banba N, Takahashi K, Emoto T, Hattori Y, Shimoda S. Elevation of plasma endothelin concentrations during endotoxin shock in dogs. Eur J Pharmacol. 1991; 205: 277-82.

[19] Voerman HJ, Stehouwer CD, Van Kamp GJ, Strack van Schijndel RJ, Groenefeld AB, And Thijs LG. Plasma endothelin levels are increased during septic shock. Crit Care Med. 1992; 20: 1097-101.

[20] Lundblad R, Giercksky KE. Endothelin-concentrations in experimental sepsis: profiles of big-endothelin and endothelin 1-21 in lethal peritonitis in rats. Eur J Surg. 1995; 161(1): 9-16.

[21] Okajima K. New therapeutic implications of antithrombin III replacement in disseminated intravascular coagulation and multiple organ failure. Intensivmed. 1996; 33: 5-11.

[22] Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Attenuation of endotoxin-induced vascular injury by antithrombin III. Am J Physiol. 1996; 270: L921-30.

[23] Horie S, Ishii H, Kazama M. Heparin-like glucosaminoglycan is a receptor for antithrombin III-dependent prostacyclin production in human endothelial cells. Thromb Res. 1990; 59: 895-904.

[24] Yamauchi T, Umeda F, Inoguchi T, Nawata H. Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells. Biochem Biophys Res Comm. 1989; 29: 1404-11.

[25] Kainoh M, Imai R, Umetsu T, Hattori M, Nishio S. Prostacyclin and beraprost sodium as suppressor of activated rat polymorphnuclear leucocytes. Biochem Pharmacol. 1990; 38: 477-84.

[26] Eisenhut T, Sinha B, Grottrup-Wolfers E, Semmler J, Siess W, Endres S. Prostacyclin analogs suppress the synthesis of tumor necrosis factor-alpha in LPS-stimulated human peripheral blood mononuclear cells. Immunopharmacology. 1993; 26: 259-64.

[27] Rubanyi GM, Polokoff MA. Endothelins: Molecular Biology, Biochemestry, Pharmacology, Physiology, and Pathophysiology. Pharmacological Reviews. 1994; 46(3): 325-415.

[28] Marsden PA, Brenner BM. Transcriptional regulation of the endothelin 1 gene by TNF alpha. Am J Physiol. 1992; 262: C854-61.

[29] Razandi M, Pedram A, Rubin T. PGE2 and PGI2 inhibit ET-1 secretion from endothelial cells by stimulating particulate guanylate cyclase. Am J Physiol. 1996; 270: H1243-9.

[30] http://www.dadachemestry.com/clinicalhtm/antithro.htm , 3/4/98

[31] http://attila.stevens-tech.edu/~caymes/thrombin.hzm , 3/10/98

[32] Takeya H, Gabazza EC, Deguchi H, Suzuki K. Recepter for thrombin-antithrombin III complex. http://www.medic.mie-u.ac.jp/posters/DM0413/DM0413.html

[33] Karlson P. Kurzes Lehrbuch der Biochemie für Mediziner und Naturwissenschaftler 13.Auflage. Georg Thieme Verlag Stuttgart-New York. 1988; 435-6.

[34] Siegenthaler W, Kaufmann W, Hornbostel H, Waller HD. Lehrbuch der Inneren Medizin 3.Auflage. Georg Thieme Verlag Stuttgart-New York. 1992; 216.

[35] ebenda. 759-60.

[36] Hickey KA, Rubanyi GM, Paul R, Highsmith RF. Characterization of a coronary vaso-constrictor produced by cultured endothelial cells. Am J Physiol. 1985; 248: C550-6.

[37] Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988; 332: 411-5.

[38] Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, Masaki T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three seperate gene. Proc Natl Acad Sci USA. 1989; 86: 2863-7.

[39] Shimada K, Takahashi M, Ikeda M, Tanzawa K. Identification and characterization of two isoforms of endothelin-converting enzyme-1. FEBS Lett. 1995; 371: 140-4.

[40] Schweizer A, Valdenaire O, Nelbock P, Deuschle U, Dumas-Milne-Edwards JB, Stumpf JG, Loffler BM. Human endothelin-converting enzyme (ECE-1): three isoforms with distinct subcellular localizations. Biochem J. 1997; 328(Pt3): 871-7.

[41] Emoto N, Yanagisawa M. Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J Biol Chem. 1995; 270: 15262-68.

[42] Levin ER. Endothelins. N Engl J Med. 1995; 333(6): 356-63.

[43] Takeda Y, Itoh Y, Yoneda T, Miyamori I, Takeda R. Cyclosporine A induces endothelin-1 release from cultured rat vascular smooth muscle cells. Eur J Pharmacol. 1993; 233: 299-301.

[44] Nunez DJR, Brown MJ, Davenport AP, Neylon CB, Schofield JP, Wye RK. Endothelin-1 mRNA is widely expressed in porcine and human tissue. J Clin Invest. 1990; 85: 1537-41.

[45] Bloch KD, Eddy RL, Shoes TB, Quertermous T. cDNA cloning and chromosomal assignment of the gene encoding endothelin-3. J Biol Chem. 1989; 264: 18156-61.

[46]Bakris GL, Fairbanks R, Traish M. Arginine vasopressin stimulates human mesangial cell production of endothelin. J Clin Invest. 1991; 87: 1158-64.

[47]Russell FD, Skepper JN, Davenport AP. Human endothelial cells storage granules: a novel intracellular site for isoforms of the endothelial-converting enzym. Circ Res. 1998; 83(3): 314-21.

[48] Inoue A, Yanagisawa M, Takuwa Y, Mitsui Y, Kobayashi M, Masaki T. The human preproendothelin-1 gene. Complete nucleotide and regulation of expression. J Biol Chem. 1989; 264: 14954-9.

[49] De Nucci G, Thomas R, D`Orlean-Juste P, Antunes E, Walder C, Warner TD, Vane JR. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA. 1988; 85: 9797-800.

[50] Dupuis J, Stewart DJ, Cernacek P, Gosselin G. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation. 1996; 94(7): 1578-84.

[51] Sofia M, Faraone S, Alifano M, Micco A, Albisinni R, Maniscalco M, Di-Minno G. Endothelin abnormalities in patients with pulmonary embolism. Chest. 1997; 111(3): 544-9.

[52] Highsmith RF, Blackburn K, Schmidt DJ. Endothelin and calcium dynamics in vascular smooth muscle. Ann Rev Physiol. 1992; 54: 257-77.

[53] Yoshimoto S, Ishizaki Y, Sazaki T, Murota SI. Effects of carbon dioxide and oxygen in endothelin production by cultured porcine cerebral endothelial cells. Stroke. 1991; 22: 378-83.

[54] Bolger GT, Liard F, Krogsrud R, Thibeault D Jaramillo J. Tissue specifity of endothelin binding sites. J Cardiovasc Pharmacol. 1990; 16: 367-75.

[55] Tamirisa P, Frishman WH, Kumar A. Endothelin and endothelin antagonism: Roles in cardiovascular health and disease. Am Heart J. 1995; 130: 601-10.

[56] Karne S, Jayawickreme CK, Lerner MR. Cloning and characterization of an endothelin-3 specific receptor (ETC receptor) from Xenopus laevis dermal melanophores. J Biol Chem. 1993; 268: 19126-33.

[57] Douglas SA, Ohlstein EH. Signal transductions mechanisms mediating the vascular actions of endothelin. J Vasc Res. 1997; 34: 152-64.

[58] Simonson MS, Dunn MJ. Cellular signaling by peptides of the endothelin gene family. FASEB J. 1990; 4: 2989-3000.

[59] Aramori I, Nakanishi S. Coupling of two endothelin receptor subtypes to differing signal transduction in transfected Chinese hamster ovary cells. J Biol Chem. 1992; 267: 12468-74.

[60] Koh E, Morimoto S, Kim S, Nabata T, Miyashita Y, Ohihara T. Endothelin stimulates Na+/H+ exchange in vascular smooth muscle cells. Biochem Int. 1990; 20: 375-80.

[61] Warner TD, Allcock GH, Mickley EJ, Corder R, Vane JR. Comperative studies with endothelin receptor antagonists BQ-123 and PD 142893 indicate at least three endothelin receptors. J Cardiovasc Pharmacol. 1989; 22(suppl 8): 117-20.

[62] Douglas SA, Beck GR Jr, Elliott JD, Ohlstein EH. Pharmacological evidence ror the presence of three distinct functional endothelin receptor subtypes in the rabbit lateral saphenous vein. Br J Pharmacol. 1995; 114: 1529-40.

[63] Kimura S, Kasuya Y, Sawamura T, Shinimi O, Sugita Y, Yanagisawa M, Goto K, Masaki T. Conversion of big endothelin-1 to 21-residue endothelin-1 is essential expression of full vasoconstrictor activity: structure activity relationships of big endothelin-1. J Cardiovasc Pharmacol. 1989; 13(suppl 5): 5-7.

[64] Hemsen A, Ahlborg G, Ottosson-Seeberger A, Lundberg JM. Metabolism of big endothelin-1 (1-38) and (22-28) in the human circulation in relation of production of endothelin (1-21). Regul Pept. 1995; 55: 287-97.

[65] Hemsen A, Pernow J, Lundberg JM. Regional extraction of endothelins and conversion of big endothelin to endothelin-1 in the pig. Acta Physiol Scand. 1991; 141: 325-34.

[66] Neuser D, Steinke W, Dellweg H, Kazda S, Stasch JP. 125I-endothelin-1 125I-big endothelin-1 in rat tissues: autoradiographic localization and receptor binding. Histochemestry. 1991; 95: 621-8.

[67] Rossi GP, Albertin G, Franchin E, Sacchetto A, Cesari M, Palu G, Pessina AC. Expression of the endothelin-converting enzyme gene in human tissue. Biochem Biophys Res Commun. 1995; 211: 249-53.

[68] Noll G, Wenzel RR, Lüscher TF. Endothelin and endothelin antagonists: Potential role in cardiovascular and renal disease. Mol Cell Biochem. 1996; 157: 259-67.

[69] Cocks TM, Broughten A, Dib M, Sudhir K, Angus JA. Endothelin is blood vessel selective: studies of a variety of human and dog vessels in vitro and regional blood flow in conscious rabbit. Clin Exp Pharmacol Physiol. 1989; 16: 243-6.

[70] Ushio-Fukai M, Nishimura J, Aoki H, Kobayashi S, Kanaide H. Endothelin-1 inhibits and enhances contraction of porcine coronary arterial strips with an intact endothelium. Biochem Biophys Res Commun. 1992; 184: 518-24.

[71] Schmeck J, Koch T. Die Bedeutung von Endothelin für physiologische und pathophysiologische Prozesse der Lunge. Anästhesiol Intensivmed Notfallmed Schmerzther. 1997; 32: 401-8.

[72] Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Path FRC, Stewart DJ. Expression of endothelin-1 in lungs of patients with pulmonary hypertension. N Engl J Med. 1993; 328: 1732-39.

[73] Kohan DE, Padilla E. Osmolar regulation of endothelin-1 production by rat inner medularry collecting duct. J Clin Invest. 1993; 91: 1235-40.

[74] Endo T, Uchida Y, Matsumoto H, Suzuki N, Nomura A, Hirata F, Hasegawa S. Regulation of endothelin-1 synthesis in cultured guinea pig airway epithelial cells by various cytokines. Biochem Biophys Res Commun. 1992; 186: 1594-99.

[75] Mattoli S, Mezetti M, Riva G, Allegra L, Fasoli A. Specific binding of endothelin on human bronchial smooth muscle cells in culture and secretion of endothelin-like material from bronchial epithelial cells. Am J Resp Cell Mol Biol. 1990; 3: 145-51.

[76] Ehrenreich H, Anderson RW, Fox CH, Rieckmann P, Hoffman GS, Travis WD, Coligan JE, Kehrl JH, Fauci AS. Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med. 1990; 172: 1741-8.

[77] Mann J, Farrukh IS, Michael JR. Mechanisms by which endothelin-1 induces pulmonary vasoconstriction in the rabbit. J Appl Physiol. 1991; 71: 410-6.

[78] Candenas ML, Naline E, Sarria B, Advenier C. Effects of epithelium removal and of enkephalin inhibition on the bronchoconstrictor response to three endo-thelins of the human isolated bronchus. Eur J Pharmacol. 1992; 210: 291-7.

[79] Millul V, Lagente V, Gillardeaux O, Boichot E, Dugas B, Mecia-Heurta JH, Bereziat G, Braquet P, Masliah J. Activation of guinea pig alveolar macrophages by endothelin-1. J Cardiovasc Pharmacol. 1991; 17(Suppl 7): 233-5.

[80] Schrör K, Seidel H. Blood-vessel wall arachidonate metabolism and ist pharmacological modification in a new in vitro system. Naunyn-Schmiedeberg´s Arch Pharmacol. 1988; 337: 177-82.

[81] Bortz J, Lienert GA, Boehnke K. Verteilungsfreie Methoden in der Biostatistik. Springer, Berlin. 1990.

[82] Uhlig S, Brasch F, Wollin L, Fehrenbach H, Richter J, Wendel A. Functional and fine structural changes in isolated rat lungs challenged with endotoxin ex vivo and in vitro. Am J Pathol. 1995; 146: 1235-47.

[83] Fourier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemand J. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest. 1993; 104: 882-8.

[84] Dickneite G, Paques EP. Reduction of mortility with antithrombin III in septicemic rats: a study of Klebsiella pneumoniae induced sepsis. Thromb Haemostas. 1993; 69: 98-102.

[85] Brunner F. Dependence of endothelin-1 secretion on Ca2+. Biochem Pharmacol. 1995; 49: 1785-91.

[86] Friedrichs GS, Kilgore KS, Maley PJ, Gralinski MR, Luccesi MR. Effects of heparin and N-acetyl heparin on ischemia/reperfusion-induced alterations in myocardial function in the rabbit isolated heart. Circ Res. 1994; 75: 701-10.

[87] Matsumoto H, Sasaki Y. Staurosporin, a protein kinase C inhibitor, interferes with proliferation of arterial smooth muscle cells. Biochem Biophys Res Commun. 1989; 158: 105-9.

[88]. Dean NM, Kanemitsu M, Boynton AL. Effects of the tyrosine-kinase inhibitor genistein on DANN synthesis and phopholipid-derived second messenger generation in mouse 10T1/2 fibroblasts and in rat liver T51B cells. Biochem Biophys Res Commun. 1989; 165: 795-801.

[89] Snapper JR, Thabes JS, Lefferts PL, Lu WX. Role of endothelin in endotoxin-induced sustained pulmonary hypertension in sheep. Am J Respir Crit Care Med. 1998; 157: 81-8.

[90] Ortega-Mateo A, de-Artinano AA. Highlights on endothelins: a review. Pharmacol-Res. 1997; 36(5): 339-51.

[91] Ahlborg G, Lundberg JM. Cyclooxygenase inhibition potentiates the renal vascular response to endothelin-1 in humans. J-Appl-Physiol. 1998; 85(5): 1661-6.

[92] Guo Y, Cernacek P, Giaid A, Hussain SN. Production of endothelins by the ventilatory muscles in septic shock. Am-J-Respir-Cell-Mol-Biol. 1998; 19(3): 470-6.

[93] Saleh D, Furukawa K, Tsao S, Maghazachi A, Corrin B, Yanagisawa M, Barnes PJ, Giaid A. Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible role of proinflammatory cytokines. Am J Respir Cell Mol Biol. 1997; 16: 187-93.

[94] Ghofrani HA, Rosseau S, Walmrath D, Kaddus W, Kramer A, Grimminger F, Lohmeyer J, Seeger W. Compartmentalized lung cytokin release in response to intravascular and alveolar endotoxin challenge. Am J Physiol. 1996; 270: L62-8.

[95] Dschietzig T, Alexiou K, Laule M, Becker R, Schroer K, Baumann G, Brunner F, Stangl K. Effect of Antithrombin III on the release of prostanoids and endothelins in isolated rat lungs under basal and septic conditions. Crit Care. in press 2000.

[96] Corder R, Vane JR. Radioimmunoassay evidence that the pressor effect of big endothelin-1 is due to local conversion to endothelin-1. Biochem Pharmacol. 1995; 49: 375-80.

[97] Hisaki K, Matsumura Y, Maekawa H, Fujita K, Takaoka M, Morimoto S. Conversion of big ET-1 in the rat lung: role of phosphoramidon-sensitive endothelin-1-converting enzyme. Am J Physiol. 1994; 266: H422-8.

[98] Helset E, Lindal S, Olsen R, Myklebust R, Jorgensen L. Endothelin-1 causes sequential trapping of platelets and neutrophils in pulmonary microcirculation in rats. Am J Physiol. 1996; 271: L538-46.

[99] Helset E, Ytrehus K, Tveita T, Kjaeve J, Jorgensen L. Endothelin-1 causes accumulation of leucocytes in pulmonary circulation. Circ Shock. 1994; 44(4): 201-9.

[100] Kurose I, Miura S, Fukumura D, Tsuchiya M. Mechanism of endothelin-induced macromolecular leakage in microvascular beds of rat mesentery. Eur J Pharmacol. 1993; 250: 85-90.

[101] Ishizaki T, Shigimori K, Nakai T, Miyabo S, Hayakawa M, Ozawa T, Voelkel NF, Chang SW. Endothelin-1 potentiats leukotoxin-induced edematous lung injury. J Appl Physiol. 1995; 79: 1106-11.

[102] Cunningham ME, Huribal M, Bala RJ, McMillen MA. Endothelin-1 and endothelin-4 stimulate monocyte production of cytokines. Crit Care Med. 1997; 25: 958-64.

[103] Stangl K, Dschietzig T, Laule M, Alexiou K, Wernecke KD, Baumann G. Pulmonary big endothelin affects coronary tone and leads to enhanced ETA-mediated coronary constriction in early endothelial dysfunction. Circulation. 1997; 96: 3192-200.

[104] Dschietzig T, Laule M, Alexiou K, Schrör K, Baumann G, Stangl K. Coronary constriction and consequent cardiodepression in pulmonary embolism are mediated by pulmonary big endothelin and enhanced in early endothelial dysfunction. Crit Care Med. 1998; 26: 510-7.

[105] Bornkessel B. Endothelinrezeptor-Antagonisten. MMP. 1997; 7: 174-6.

[106] Filep JG. Endothelin receptor antagonists: new perspectives in endothelin research. Drugs Today. 1995; 31: 155-71.

[107] Kaddoura S, Poole-Wilson PA. Endothelin-1 in heart failure: a new therapeutic target? Lancet. 1996; 348: 418-9.

[108] Ikeda H, Kubo N, Nakamura A, Harada N, Yamashita T. Intracellular Ca2+ mobilization in cultured human mucosal microvascular endothelial cells from the nasal inferior turbinate. ORL J Otorhinolaryngol Relat Spec. 1996; 58(6): 320-5.

[109] van Bremen C, Skarsgard P, Laher I, McManus B, Wang X. Endothelium-smooth muscle interactions in blood vessels. Clin Exp Pharmacol Physiol. 1997; 24(12): 989-92.

[110] Liu JJ, Casley D, Wojta J, Gallicchio M, Dauer R, Buxton BF, Johnston CI. Reduction of endothelin levels by the dihydropyridine calcium antagonist nisoldipine and a natural factor in cultured human endothelial cells. J Hypertens. 1993; 11: 977-982.

[111] Chen TH, Tseng HP, Yang YJ, Mao SJ. Effect of antioxidant in endothelial cells exposed to oxidized low-density lipoproteins. Life-Sci. 1998; 62(19): PL277-82.

[112] Stangl K, Dschietzig T, Alexiou K, Brunner F. Antithrombin increases pulmonary endothelins: inhibition by heparin and Ca2+ channel antagonism. Eur J Pharmcol. 1999; 370(1): 57-61.

[113] Imai T, Hirata Y, Emori T, Marumo F. Heparin has an inhibitory effect on endothelin-1 synthesis and release by endothelial cells. Hypertension. 1993; 21: 353-358.

[114] Marsen TA, Simonson MS, Dunn MJ. Thrombin induces the preproendothelin-1 gene in endothelial cells by a protein tyrosine kinase-linked mechanism. Circ Res. 1995; 76: 987-995.

[115] Kusaka M, Sperelakis N. Inhibition of L-type calcium current by genistein, a tyrosine kinase inhibitor, in pregnant rat myometrial cells. Biochim Biophys Acta. 1995; 1240: 196-200.

[116] Molnar M, Hertelendy F. Signal transduction in rat myometrial cells: comparisons of the actions of endothelin-1, oxytocin and prostaglandin F2 alpha. Eur J Endocrinol. 1995; 133(4): 467-74.

[117] Mathias RS, Mikoshiba K, Michikawa T, Miyawaki A, Ives HE. IP3 receptor blockade fails to prevent intracellular Ca2+ release by ET-1 and alpha-thrombin. Am J Physiol. 1998; 274: C1456-65.

[118] Zhang W, Sarosi G Jr, Barnhart D, Yuli DI, Mulholland MW. Endothelin-activated calcium signal in enteric glia derived from neonatal guinea pig. Am J Physiol. 1997; 272: G1175-85.

[119] Liu S, Smith SE, Julien J, Rohde LH, Karin NJ, Carson DD. cDNA cloning and expression of HIP, a novel cell surface heparan sulfate/heparin-binding protein of human uterine epithelial cells and cell lines. J Biol Chem. 1996; 271(20): 11817-23.

[120] Liu S, Julien J, Carson DD. A peptide sequence of heparin/heparan sulfate (HP/HS) interacting protein supports selective, high affinity binding of HP/HS and cell attachment. J Biol Chem. 1998; 273(16): 9718-26.

[121] Pinhal MA, Santos IA, Silva IF, Dietrich CP, Nader HB. Minimum fragments of the heparin molecule able to produce the accumulation and change of the sulfation pattern of the antithrombotic heparan sulfate from endothelial cells. Thromb Haemost. 1995; 74(4): 1169-74.


[Titelseite] [1] [2] [3] [4] [5] [6] [7] [8] [Bibliographie] [Danksagung] [Lebenslauf] [Selbständigkeitserklärung]

© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.

DiML DTD Version 2.0
Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML - Version erstellt am:
Wed Nov 15 13:47:58 2000